Profile: Surmodics Inc (SRDX.O)
24 May 2019
Surmodics, Inc., incorporated on June 27, 1979, is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's business segments partner with medical device, diagnostic and life science companies to develop and commercialize products designed to improve patient diagnosis and treatment. As of September 30, 2016, the Company had over 150 licensed product classes (customer products utilizing Surmodics technology) in the market generating royalties and over 100 customer product classes incorporating its technology in various stages of pre-commercialization.
The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. Its end markets include coronary, peripheral, neuro-vascular and urology. With its drug-coated balloon (DCB) platform, the Company is focused on developing and manufacturing medical device products that combine its surface modification coatings with medical devices or delivery systems (whole-product solutions). It focuses on the development of drug coated balloons to treat peripheral artery disease (PAD). The Company's PhotoLink is a coating technology that modifies medical device surfaces by creating covalent bonds between device surfaces and a range of chemical agents. Its PhotoLink reagents can be applied to various substrates. The coating formulations are applied to the material surface by various methods, including dipping, spraying, roll coating or ink jetting.
In Vitro Diagnostics
The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. It manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. It offers protein stabilization reagents, substrates, antigens and surface coatings. The Company offers a line of stabilization products for the in vitro diagnostics market. The Company also provides colorimetric and chemiluminescent substrates to the in vitro diagnostics market under its BioFX trademark. It is a distributor in the United States, Canada and Puerto Rico (and non-exclusive distributor in Japan) of DIARECT AG's line of antigens. The Company offers custom coatings for molecular diagnostic applications, including deoxyribonucleic acid (DNA), ribonucleic Acid (RNA) and protein microarrays. Its TRIDIA surface coatings bind molecules to various surfaces and geometries and may be customized for selectivity using passivating polymers and reactive groups. This technology immobilizes DNA and protein to adhere to testing surfaces.
9924 W 74th St
EDEN PRAIRIE MN 55344-3523